5 questions RWE & HEOR teams should ask data vendors in an RFP
RWE and HEOR teams face increasing pressure to produce evidence that holds up beyond internal...
RWE and HEOR teams face increasing pressure to produce evidence that holds up beyond internal...
Healthcare marketing has reached an inflection point and for years, success was defined by reach:...
Capturing the true complexity of psoriasis in the real world Psoriasis is a common chronic...
Industry trends in ulcerative colitis research: a new path Ulcerative colitis is a chronic...
New research is challenging long-held assumptions about privacy-preserving record linkage (PPRL)....
Real-world evidence (RWE) studies often stall on the same friction points: defining the most...
Alzheimer’s disease burden and the current therapy pipeline Alzheimer’s disease remains the leading...
When two federal agencies, the National Center for Science and Engineering Statistics (NCSES) and...
October is Breast Cancer Awareness Month. While pink ribbons and fundraising campaigns help bring...
In just a few years, artificial intelligence (AI) has become a trusted tool in early drug...
Rare diseases may be individually uncommon, but collectively they affect an estimated 30 million people in the United States. Yet for many patients, the path to diagnosis spans years, sometimes decades. Symptoms appear one at a time. Specialists trea...